CN105308037B - 三唑化合物及其作为γ分泌酶调节剂的用途 - Google Patents

三唑化合物及其作为γ分泌酶调节剂的用途 Download PDF

Info

Publication number
CN105308037B
CN105308037B CN201480031612.5A CN201480031612A CN105308037B CN 105308037 B CN105308037 B CN 105308037B CN 201480031612 A CN201480031612 A CN 201480031612A CN 105308037 B CN105308037 B CN 105308037B
Authority
CN
China
Prior art keywords
alkyl
pharmaceutically acceptable
acceptable salt
methyl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201480031612.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105308037A (zh
Inventor
Y.贝西德斯基
U.英格夫
K.保尔森
C.林德
G.诺德瓦尔
I.麦克萨里
J.马姆博格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akturam Real Estate Co ltd
Aztec Pharmaceuticals
Original Assignee
Acker Tula Nurse Life Sciences Joint-Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acker Tula Nurse Life Sciences Joint-Stock Co filed Critical Acker Tula Nurse Life Sciences Joint-Stock Co
Publication of CN105308037A publication Critical patent/CN105308037A/zh
Application granted granted Critical
Publication of CN105308037B publication Critical patent/CN105308037B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201480031612.5A 2013-06-04 2014-06-03 三唑化合物及其作为γ分泌酶调节剂的用途 Expired - Fee Related CN105308037B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE1350683 2013-06-04
SE1350683-7 2013-06-04
PCT/EP2014/061498 WO2014195321A1 (en) 2013-06-04 2014-06-03 Triazole compounds and their use as gamma secretase modulators

Publications (2)

Publication Number Publication Date
CN105308037A CN105308037A (zh) 2016-02-03
CN105308037B true CN105308037B (zh) 2017-09-19

Family

ID=50884402

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480031612.5A Expired - Fee Related CN105308037B (zh) 2013-06-04 2014-06-03 三唑化合物及其作为γ分泌酶调节剂的用途

Country Status (5)

Country Link
US (1) US9611254B2 (https=)
EP (1) EP3004081B1 (https=)
JP (1) JP6368776B2 (https=)
CN (1) CN105308037B (https=)
WO (1) WO2014195321A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3212641B1 (en) 2014-10-30 2018-12-05 Janssen Pharmaceutica NV Thiazoles as modulators of roryt
TWI667230B (zh) 2014-10-30 2019-08-01 比利時商健生藥品公司 用作ＲＯＲγｔ調節劑之三氟甲基醇
TW201803869A (zh) 2016-04-27 2018-02-01 健生藥品公司 作為ＲＯＲγＴ調節劑之６－胺基吡啶－３－基噻唑
ES2925473T3 (es) 2018-06-18 2022-10-18 Janssen Pharmaceutica Nv Pirazoles de piridinilo como moduladores de RORyt
CA3103770A1 (en) 2018-06-18 2019-12-26 Janssen Pharmaceutica Nv Phenyl and pyridinyl substituted imidazoles as modulators of roryt
EP3806958B1 (en) 2018-06-18 2022-09-07 Janssen Pharmaceutica NV 6-aminopyridin-3-yl pyrazoles as modulators of roryt
JP2021528405A (ja) 2018-06-18 2021-10-21 ヤンセン ファーマシューティカ エヌ．ベー． ＲＯＲγｔのモジュレータとしてのアミド置換チアゾール

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102906083A (zh) * 2010-01-15 2013-01-30 杨森制药公司 作为γ分泌酶调节剂的新的取代的三唑衍生物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20030312A1 (it) 2003-02-21 2004-08-22 Chiesi Farma Spa Derivati di acidi 2-fenil-2-alchil-acetici per il trattamento della malattia di alzheimer.
US20080153817A1 (en) 2003-08-07 2008-06-26 Dirk Beher Treatment for Alzheimer's Disease and Related Conditions
DE602004023762D1 (de) 2003-12-03 2009-12-03 Merck Sharp & Dohme Für die behandlung von alzheimer-krankheit und ähnlichen leiden geeignete 1-alkyl-3-thiosubstituierte indol-2-alkinsäuren
MY149038A (en) 2004-05-26 2013-07-15 Eisai R&D Man Co Ltd Cinnamide compound
WO2007125364A1 (en) 2006-04-26 2007-11-08 Merck Sharp & Dohme Limited Piperidines and related compounds for treatment of alzheimer’s disease
KR20090018963A (ko) 2006-05-19 2009-02-24 에자이 알앤드디 매니지먼트 가부시키가이샤 우레아계 신나미드 유도체
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
JP2010518080A (ja) 2007-02-08 2010-05-27 メルク・シャープ・エンド・ドーム・コーポレイション 治療薬
EP2120573A4 (en) 2007-02-12 2011-05-25 Merck Sharp & Dohme piperidine
CA2676715A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
EP2166854A4 (en) 2007-06-13 2012-05-16 Merck Sharp & Dohme TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED SUFFERINGS
MX2010001506A (es) 2007-08-06 2010-03-10 Schering Corp Moduladores de gamma secretasa.
ES2375919T3 (es) 2008-01-11 2012-03-07 F. Hoffmann-La Roche Ag Moduladores de beta-amiloide.
MX2010008700A (es) 2008-02-22 2010-08-30 Hoffmann La Roche Moduladores de beta-amiloide.
US8642583B2 (en) * 2008-10-30 2014-02-04 Janssen Pharmaceutica Nv Serotonin receptor modulators
CA2742897A1 (en) 2008-11-06 2010-05-14 Astrazeneca Ab Modulators of amyloid beta.
CN102209537A (zh) 2008-11-10 2011-10-05 弗·哈夫曼-拉罗切有限公司 杂环γ分泌酶调节剂
TW201030002A (en) 2009-01-16 2010-08-16 Bristol Myers Squibb Co Bicyclic compounds for the reduction of beta-amyloid production
ES2590987T3 (es) * 2009-04-29 2016-11-24 Glaxo Group Limited Derivados de 5,6,7,8-tetrahidro[1,2,4]triazolo[4,3-a]pirazina como moduladores de P2X7
UY32622A (es) 2009-05-12 2010-12-31 Astrazeneca Ab Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta)
JP2012532912A (ja) 2009-07-15 2012-12-20 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド ガンマセクレターゼモジュレーターとしての置換されたトリアゾールおよびイミダゾール誘導体
TWI468402B (zh) 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
US20110190269A1 (en) * 2010-02-01 2011-08-04 Karlheinz Baumann Gamma secretase modulators
TW201206946A (en) 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
AU2012230348A1 (en) * 2011-03-24 2013-08-29 Cellzome Limited Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102906083A (zh) * 2010-01-15 2013-01-30 杨森制药公司 作为γ分泌酶调节剂的新的取代的三唑衍生物

Also Published As

Publication number Publication date
WO2014195321A1 (en) 2014-12-11
EP3004081A1 (en) 2016-04-13
JP2016520635A (ja) 2016-07-14
US9611254B2 (en) 2017-04-04
CN105308037A (zh) 2016-02-03
EP3004081B1 (en) 2017-11-15
US20160122326A1 (en) 2016-05-05
JP6368776B2 (ja) 2018-08-01

Similar Documents

Publication Publication Date Title
CN105308037B (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
CN107787323B (zh) 用于抑制shp2活性的化合物和组合物
EP3022202B1 (en) Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
TW201945357A (zh) 化合物
JP5621148B2 (ja) ５−ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール−３−カルボキサミド誘導体
CN105142635A (zh) 有用于治疗疾病的杂环化合物
BR112012004533B1 (pt) Composto, composição farmacêutica, e uso do composto
CN105263923B (zh) 嘧啶化合物及它们作为γ分泌酶调节剂的用途
CN103917534B (zh) 作为h3受体抑制剂的包含哌啶和哌嗪环的氨基甲酸酯/脲衍生物
CN108026050A (zh) 作为RORγ调节剂的新型化合物
EA021543B1 (ru) Сульфонилпиразольные и сульфонилпиразолиновые производные карбоксамидина как антагонисты 5-ht
CN105263922B (zh) 三唑化合物及其作为γ分泌酶调节剂的用途
CN107827841A (zh) 作为Rorγt调节剂的三氟甲基醇
CN104395293A (zh) 2h-咪唑-4-胺化合物及其作为bace抑制剂的用途
CN108463462B (zh) 苯二氮䓬类作为溴结构域抑制剂
CN106459041B (zh) 嘧啶并[4,5-b]喹啉-4,5(3H,10H)-二酮衍生物
CN107739378A (zh) 吲哚嗪衍生物及其在医药上的应用
KR20190104195A (ko) 치환된 3-디알킬아미노메틸-피페리딘-4-일-벤즈아미드 및 이를 제조 및 사용하는 방법
BR112017005241B1 (pt) Composto, composição farmacêutica, e, uso de um composto
JP6401254B2 (ja) プロキネシチン受容体のモジュレータとしての１−スルホニルピペリジン誘導体
US20240390355A1 (en) Irhom2 inhibitors and uses thereof
CN107074777A (zh) 苄基醇衍生物、其制备方法及其治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20191016

Address after: Solna, Sweden

Patentee after: Akturam Real Estate Co.,Ltd.

Address before: Swedish Suo de Jie

Patentee before: ACTURUM LIFE SCIENCE AB

Effective date of registration: 20191016

Address after: Hu Dinge, Sweden

Patentee after: Aztec Pharmaceuticals

Address before: Solna, Sweden

Patentee before: Akturam Real Estate Co.,Ltd.

CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170919